Oxford Biomedica PLC Director/PDMR Shareholding (6138X)
August 13 2018 - 5:55AM
UK Regulatory
TIDMOXB
RNS Number : 6138X
Oxford Biomedica PLC
13 August 2018
PDMR Dealings / Market Share Sale
Oxford, UK - 13 August 2018: Oxford BioMedica plc ("Oxford
BioMedica" or "the Company") (LSE: OXB), a leading gene and cell
therapy group, was informed that on 09 August 2018 James Miskin,
Chief Technical Officer, exercised 11,759 options at 50p, exercised
500 options at 287.5p and 814 options at 141.5p and sold all of the
resulting shares at 904.416p.
Following this transaction he holds 163,272 options and no
shares in the company.
The issued share capital of the Company is 65,752,788 ordinary
shares of 50 pence each.
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the EU Market Abuse
Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name James Miskin
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Chief Technical Officer
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford BioMedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- -----------------------------------
b) Nature of the Exercise of options
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP0.500 11,759
----------
GBP2.875 500
----------
GBP1.415 814
----------
----------------------------- -----------------------------------
e) Aggregated information 13,073
* Aggregate volume GBP0.648
GBP8,468.81
* Price
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2018-08-09
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name James Miskin
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Chief Business Officer
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford BioMedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- -----------------------------------
b) Nature of the Disposal
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP9.04416 13,073
----------
----------------------------- -----------------------------------
e) Aggregated information 13,073
* Aggregate volume GBP9.04416
GBP118,234.30
* Price
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2018-08-09
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
-Ends-
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865 783 000
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Financial and corporate communications Tel: +44 (0)20 3709 5700
enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia
Manser/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Bioverativ, Sanofi, Axovant,
Orchard Therapeutics, GC LabCell and Immune Design, through which
it has long-term economic interests in other potential gene and
cell therapy products. Oxford BioMedica is based across several
locations in Oxfordshire, UK and employs more than 320 people.
Further information is available at www.oxfordbiomedica.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHGCGDIGUBBGIX
(END) Dow Jones Newswires
August 13, 2018 05:55 ET (09:55 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024